Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 3Thoracic 2Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 39Rectal Neoplasms 11Colonic Neoplasms 11Neoplasms 10Neoplasm Metastasis 9Stomach Neoplasms 4Ovarian Neoplasms 3Gastrointestinal Neoplasms 3Pancreatic Neoplasms 2Lung Neoplasms 2Adenocarcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Exanthema 1Colorectal Cancer Metastatic 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma, Basal Cell 1Carcinoma 1Breast Neoplasms 1Advanced Cancer 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × IFL protocol × Clear all
NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Genentech, Inc.

Phase 2 Completed
19 enrolled 10 charts
DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

NCT03250832 2024-04-11

CITRINO

Tesaro, Inc.

Phase 1 Completed
111 enrolled 48 charts
GastrointestinalGynecologicThoracic

Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02033551 2016-09-27

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
47 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡